

# Hepatocellular Carcinoma Pathways

---

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_

Stage: \_\_\_\_\_

Line of Therapy: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_

## First Line of Therapy (1<sup>st</sup> Line)

- Stages II-IVB, and Recurrent - Unresectable and Metastatic Disease
  - Atezolizumab and bevacizumab
  - Sorafenib

## Second Line of Therapy (2<sup>nd</sup> Line)

- Stages II-IVB, and Recurrent - Unresectable and Metastatic Disease
    - Cabozantinib
    - Regorafenib
- 

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue  
South Tower – Suite 800 Chicago, IL 60631

Last review: 5/10/2022 | Effective date: 5/10/2022

© 2023 Carelon Medical Benefits Management